International Journal of
Reproductive Biomedicine
Sun, Dec 29, 2024
[Archive]
Volume 10, Issue 2 (7-2012)
IJRM 2012, 10(2): 127-130 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moini A, Javanmard F, Eslami B, Aletaha N. Prevalence of metabolic syndrome in polycystic ovarian syndrome women in a hospital of Tehran. IJRM 2012; 10 (2) :127-130
URL: http://ijrm.ir/article-1-264-en.html
URL: http://ijrm.ir/article-1-264-en.html
1- Department of Obstetrics and Gynecology, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran , hosp_arash@tums.ac.ir
2- Department of Obstetrics and Gynecology, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran
3- Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Obstetrics and Gynecology, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran
3- Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (3395 Views)
Background: Polycystic ovarian syndrome (PCOS) is a condition associated with chronic anovulation, insulin resistance and androgen excess. Women with this syndrome are at increased risk of metabolic syndrome.
Objective: The aim of the present study was to determine the prevalence of metabolic syndrome (MBS) in women with PCOS referred to Arash Hospital in different ages and body mass index (BMI).
Materials and Methods: A cross-sectional study was conducted in Gynecologic Clinic at Arash Hospital affiliated with Tehran University. A total of 282 women with PCOS ages between 15-40 years were included. The prevalence of Metabolic Syndrome and its components in this population were the main outcomes. Height, weight, waist circumference, blood pressure and laboratory tests (FBS, TSH, HDL-C, serum prolactin, triglycerides and total cholesterol) were measured in this population.
Results: The prevalence of MBS in PCOS women was 22.7% (64 cases). The rate of central obesity, FBS more than 110 mg/dl, triglycerides more than 150 mg/dl, high-density lipoprotein cholesterol levels (HDL-C) less than 50 mg/dl, and blood pressure ?130/85 mmHg in PCOS women was 31% (87), 3.2% (9), 33% (93), 68.8% (194), and 10.6% (30), respectively. The risk of MBS was increased in older and the obese women (BMI ?30 kg/m2). Conclusion: The present sample showed women with PCOS have a high prevalence of MBS and its individual components, particularly decreased HDL-C.
Objective: The aim of the present study was to determine the prevalence of metabolic syndrome (MBS) in women with PCOS referred to Arash Hospital in different ages and body mass index (BMI).
Materials and Methods: A cross-sectional study was conducted in Gynecologic Clinic at Arash Hospital affiliated with Tehran University. A total of 282 women with PCOS ages between 15-40 years were included. The prevalence of Metabolic Syndrome and its components in this population were the main outcomes. Height, weight, waist circumference, blood pressure and laboratory tests (FBS, TSH, HDL-C, serum prolactin, triglycerides and total cholesterol) were measured in this population.
Results: The prevalence of MBS in PCOS women was 22.7% (64 cases). The rate of central obesity, FBS more than 110 mg/dl, triglycerides more than 150 mg/dl, high-density lipoprotein cholesterol levels (HDL-C) less than 50 mg/dl, and blood pressure ?130/85 mmHg in PCOS women was 31% (87), 3.2% (9), 33% (93), 68.8% (194), and 10.6% (30), respectively. The risk of MBS was increased in older and the obese women (BMI ?30 kg/m2). Conclusion: The present sample showed women with PCOS have a high prevalence of MBS and its individual components, particularly decreased HDL-C.
Type of Study: Original Article |
References
1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J clin Endocrinol Metab 1988; 83: 3078-3082.
2. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Harrison's principles of internal medicine; 17th Ed. 2008: 1509-1513.
3. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421. [DOI:10.1161/circ.106.25.3143]
4. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52: 908-915. [DOI:10.1016/S0026-0495(03)00104-5]
5. Apridonize T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929-1935. [DOI:10.1210/jc.2004-1045]
6. Lankarani M, Valizadeh N, Heshmat R, Peimani M, Sohrabvand F. Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 504-507. [DOI:10.1080/09513590902972083]
7. Hosseinpanah F, Barzin M, Tehrani FR, Azizi F. The lack of association between polycystic ovary syndrome and metabolic syndrome: Iranian PCOS prevalence study. Clin Endocrinol 2011; 19: 692-697. [DOI:10.1111/j.1365-2265.2011.04113.x]
8. Revised 2003 Consensus on diagnosis criteria and long-term health risks related to poly cystic ovarian syndrome (PCOS). Hum Reprod 2004; 9: 41-47.
9. Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhao TM. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil Steril 2008; 89: 649-655. [DOI:10.1016/j.fertnstert.2007.03.081]
10. Cheung LP, Ma RC, Lam PM, Lok IH, Haines CJ, So WY, et al. Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod 2007; 23: 1431-1438. [DOI:10.1093/humrep/den090]
11. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose study. Diabetes Res Cklin Pract 2003; 61: 29-37. [DOI:10.1016/S0168-8227(03)00066-4]
12. Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults: findings from the third the National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359. [DOI:10.1001/jama.287.3.356]
13. Brunner D, Weisbort J, Meshulam N, Schwartz S, Gross J, Saltz-Rennert H, et al. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty years follow up of the Donolo -Tel Aviv Prospective Coronary Artery Disease Study. Am J Cardiol 1987; 59: 1271-1276. [DOI:10.1016/0002-9149(87)90903-9]
14. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32-47. [DOI:10.1093/oxfordjournals.aje.a115483]
15. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham study. Am Heart J 1987; 114: 413-419. [DOI:10.1016/0002-8703(87)90511-4]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
